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Abstract 
BACKGROUND: Reed syndrome or multiple cutaneous leiomyomas with uterine leiomyomas are part of the 
spectrum of heterozygous hereditary disorders with cutaneous, genital and renal manifestations.  
CASE REPORTS: We report two female cases of multiple cutaneous leiomyomas with uterine leiomyomas 
(MCUL) without renal disease, in particular without cysts or papillary renal carcinoma, aged 52 and 55 years, 
respectively. The diagnosis of pilar leiomyomas was confirmed by histology and immunostaining for smooth 
muscle actin and desmin. Both females had a hysterectomy in the past because of uterus myomatosus. In one 
patient, a new mutation of the FH gene was detected, i.e. a heterozygote c1300_1301del (p.Cys434Argfs17) 
mutation in the exon 9 of the FH gene.  
CONCLUSION: Since MCUL shares features with the genetic cancer syndrome hereditary leiomyomatosis and 
renal cell carcinoma (HLRCC), these patients need a regular follow-up to prevent the late diagnosis of renal 
cancer. 
 
 
 
 
 
 
 
 
Introduction 
 
The fumarate dehydrogenase (FH) gene is 
located on chromosome 1. In normal cells, FH is 
localised in both mitochondria and cytosol and 
catalyses fumarate to malate [1].  
Fumarate is a covalent oncometabolite whose 
accumulation is characteristic for the genetic cancer 
syndrome hereditary leiomyomatosis and renal cell 
carcinoma (HLRCC). HLRCC is characterized by 
germline mutation of the fumarate hydratase (FH) 
gene, which leads to a shift to aerobic glycolysis in the 
affected cells (Warburg effect) [2]. The disease is 
autosomal dominant inherited. In homozygotes, FH 
deficiency is lethal in early childhood [3].  
In the medical literature, only about 300 cases 
of HLRCC are described with > 150 different 
mutations [4]. We report on two female patients with 
the milder type of the disease known as Reed 
syndrome or multiple cutaneous leiomyomas with 
uterine leiomyomas (MCUL; MIM 150800) and one 
new mutation. 
 
 
Case Reports 
 
Case One 
A 52-year-old Caucasian woman presented 
with multiple flat painful tumours concentrated on her 
left shoulder (Figure 1). 
Her medical history was positive for a uterus 
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myomatosus that was surgically removed by 
hysterectomy. She was otherwise healthy. 
 
Figure 1: Multiple pilar leiomyomas on the left shoulder (case #1) 
 
In her family, her mother had renal cancer at 
the age of 58 years, her son has multiple cutaneous 
leiomyomas (Fig. 2). 
On examination, we observed multiple flat, 
livid nodules that were painful on pressure. Their size 
varied between 1 and 2 cm. The lesions were 
concentrated above her left should blade, but single 
lesions were spread all over the body except 
palmoplantar skin and head and neck. 
 
Figure 2: Family tree of the Case #1 
 
We performed an excision of the most painful 
lesions. Histopathology disclosed dermal spindle cell 
tumours without cellular atypias or mitotic activity. 
The lesions were well demarcated. Tumour 
cells were positive for smooth muscle actin and 
desmin (Figure 3) but Ki67 negative. The diagnosis of 
pilar leiomyomas was confirmed. 
We performed molecular biology analysis of 
the fumarate hydrogenase (FH) gene. Extracted DNA 
was enriched by Nextera Rapid Capture on Ilumina 
NextSequ 500 followed by Sanger sequencing, 
multiplex ligation-dependent probe analysis (MPLA) to 
detect possible duplications or deletions of exons, and 
biometric analysis by MutationSurveyor version 3.10, 
GeneMarker V2 4.0 and Alamut Visual version 2.6.1 
(MVZ Mitteldeutscher Praxisverbund Humangenetik 
GmbH, Dresden). 
 
Figure 3: Desmin immunostaining of pilar leiomyoma (case #1, x 2) 
 
A heterozygote c1300_1301del 
(p.Cys434Argfs17) mutation in the exon 9 of the FH 
gene could be detected, leading to a loss of function 
for the reading frame. This mutation has not been 
described before.  
Routine laboratory investigations remained 
unremarkable. Tumour markers ICA 125 and ICEA 
were detected by chemiluminescence assays (Roche 
Diagnostics) and were within the normal range. 
She was screened by diagnostic ultrasound, 
abdominal magnetic resonance imaging, and X-ray of 
the chest. There was no hint for renal cancer or any 
other renal disorder. 
The diagnosis of MCUL (MIM 150800) was 
confirmed. 
 
 Case Two 
A 55-year-old Caucasian woman presented 
with segmental painful tiny brownish nodules and 
plaques of the left supra- and infraclavicular region 
(Figure 4). She had a hysterectomy due to a uterus 
five years ago but no other disorders. Her family 
history was unremarkable. 
A skin biopsy was taken, which disclosed 
circumscribed dermal tumours composed of 
interlacing and whorled bundles of smooth muscle 
cells expressing actin. The tumours appeared yellow-
orange in van Giessen stain. The diagnosis of pilar 
leiomyomas was confirmed. 
Screening for renal cancer by diagnostic 
ultrasound and contrast-enhanced computerised 
tomography (CT) was negative. No molecular analysis 
was available. Nevertheless, the diagnosis of MCUL 
(MIN 150800) was confirmed. This case had been 
reported earlier elsewhere [5]. Until now, no renal 
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cancer was detected in this patient.  
 
Figure 4: Pilar leiomyomas around the left clavicula (case # 2): a) 
Overview, b) detail (From Wollina U, Schönlebe J. Reed's 
syndrome: segmental piloleimyomas type 1 and uterus 
myomatosus. J Dermatol Case Rep. 2014; 8(3):67-69) [5] 
 
 
Discussion 
 
We reported two cases of MCUL, a rare 
heterozygote FH deficiency, without renal cancer. In 
the case of heterozygote FH deficiency, fumarate 
suppresses the homologous recombination DNA 
repair pathway which is necessary for the repair of 
DNA double-strand breaks and genomic integrity by 
succination of proteins. the  increases intracellular 
ferritin concentrations which drives tumour cell 
proliferation [6]. 
Hallmark of the disease is hereditary 
leiomyomatosis seen in > 75% of the affected 
patients. However, only 46% of affected individuals 
show cutaneous leiomyomas, benign smooth muscle 
tumours of the skin of the tumour. These tumours are 
sensitive to touch and cold and can be painful [7], [8]. 
Cutaneous pilar leiomyomas are benign tumours with 
an incidence of 0.04% in pathology files. Other 
cutaneous leiomyomas are angioleimyoma and 
dartoic myoma, but the pilar type if the predominant 
one responsible for 88.5% of all cases [9]. A rare 
subtype of pilar leiomyoma is represented by 
symplastic pilar leiomyoma with focal cellular 
pleomorphism [10]. This particular subtype has been 
reported to be potentially developing in 
leiomyosarcoma in rare cases [11]. 
Women with HLRCC are prone to develop 
multiple leiomyomas of the uterus as well, which leads 
to uterus myomatosus. Hysterectomy is performed in 
about 50% in patients younger than 35 years. The 
disease can cause dysmenorrhea, menorraghias, and 
menstrual irregularities [12], [13]. 
Both of our patients had a hysterectomy due 
to uterine leiomyomas. Both presented with multiple 
cutaneous pilar leiomyomas. The lesions were 
segmental in case # 2 and segmental concentrated 
with single lesions on other body parts in case # 1. 
Painful lesions were removed by surgery. 
The most dangerous feature of HLRCC, 
however, is the early onset of papillary kidney cancer 
in the affected families. This tumour has two subtypes. 
Type 1 is an indolent growing tumour associated with 
germline mutations of MET. It is found in hereditary 
papillary kidney cancer. Type 2, in contrast, is an 
aggressive tumour with early metastatic spread. This 
type is associated with HLRCC. It occurs in about 
25% of patients with an average onset at 46 years. It 
may be without specific symptoms but can cause 
lumbar back pain or hematuria. Renal cysts are also 
more common in HRLCC than in the general 
population [14].  
In case # 1, the mother of our index patient 
had an unspecified renal cancer but no 
leimyomatosis. This could be an incidental 
coincidence. In case 2, there was no family history of 
other members affected by either MCUL or HLRCC. 
Nevertheless, these patients need a regular live-long 
follow-up for early detection of renal cell cancer.  
In conclusion, MCUL may be considered a 
forme fruste of HLRCC or a more benign subtype. 
More investigations are needed. 
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